EPS for Adaptimmune Therapeutics plc (ADAP) Expected At $-0.03

October 2, 2018 - By Marguerite Chambers

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Logo

Analysts expect Adaptimmune Therapeutics plc (NASDAQ:ADAP) to report $-0.03 EPS on November, 1.After having $-0.48 EPS previously, Adaptimmune Therapeutics plc’s analysts see -93.75 % EPS growth. The stock decreased 3.66% or $0.51 during the last trading session, reaching $13.43. About 361,193 shares traded. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has risen 31.65% since October 2, 2017 and is uptrending. It has outperformed by 16.03% the S&P500.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $1.40 billion. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The company's lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

More recent Adaptimmune Therapeutics plc (NASDAQ:ADAP) news were published by: Seekingalpha.com which released: “Adaptimmune Therapeutics announces registered direct offering of ADSs” on September 05, 2018. Also Seekingalpha.com published the news titled: “Adaptimmune nets $100M in equity offering” on September 07, 2018. Nasdaq.com‘s news article titled: “Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares” with publication date: September 07, 2018 was also an interesting one.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News